Open-Label, Randomized Study to Assess Safety and Efficacy of Slow and Accelerated Switching to Xanomeline/Trospium From Standard of Care Atypical Antipsychotics in Participants With Schizophrenia

Welcome back to another Psychiatric Times Insights series. In this episode titled, "The Switch Study: Why a New Mechanism Demands a New Approach," David Walling, PhD, address the unmet clinical needs in schizophrenia treatment that motivated the development of the study evaluating the transition from atypical antipsychotics to Cobenfy?

In "Managing Tolerability and Setting Patients Up for Success with Cobenfy," David Walling, PhD, delved into the key tolerability considerations for patients with schizophrenia transitioning to Cobenfy and how clinicians should proactively manage gastrointestinal side effects?